Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q2 2022 net revenue of $121.4 million, down 1% year-over-year, with Advanced Wound Care up 2% to $113.8 million while Surgical & Sports Medicine fell 35% to $7.6 million. Net income decreased significantly by 58% to $8.7 million, or $0.07 per share. Adjusted EBITDA dropped to $18.6 million from $25.1 million a year ago. For FY 2022, the company projects revenue between $465 million and $490 million, reflecting a modest annual decline or growth.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its second quarter fiscal year 2022 financial results will be released after market close on August 9, 2022. A conference call will follow at 5:00 p.m. Eastern Time, providing an overview of the results and corporate updates. Interested participants can access the live webcast through the company's investor relations website. The archived version will also be available for roughly one year. Organogenesis specializes in regenerative medicine, focusing on products for Advanced Wound Care and Surgical & Sports Medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q1 2022 financial results with net revenue of $98.1 million, down 4% year-over-year. Revenue from Advanced Wound Care increased by 0.3% to $91.0 million, while Surgical & Sports Medicine revenue fell 39% to $7.2 million. Net income plummeted to $0.1 million from $9.9 million, a decrease of $9.9 million. Adjusted EBITDA also dropped 69% to $5.0 million. The company projects net revenue for 2022 to be between $485 million and $515 million, indicating an anticipated growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to its Board of Directors, effective May 3, 2022. Both directors bring extensive experience from various leadership roles in the healthcare industry. Korfin, with previous roles at Gamida Cell and Kite Pharma, holds an MBA from Harvard and has a strong background in market access and commercialization. Quintero has served as Chief Quality Officer at Kimberly-Clark and holds a Ph.D. in Chemistry. This move enhances the board's independence, with a majority now being independent directors.
Organogenesis announced its participation as a leading sponsor at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference in Phoenix, Arizona, from April 6-10, 2022. The company will present new research on its wound care products, including PuraPly® AM and Apligraf®. Key events include a breakfast symposium on randomized controlled trials and an Innovation Theatre lunch discussing chronic wound treatment. Attendees can visit booth #703 for insights into the latest advanced wound care solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal 2022 financial results after market close on May 10th. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update, including a Q&A session. Participants can join by dialing 866-795-3142 or 409-937-8908 for international calls, using access code 3349739. A live webcast will also be available on the company's investor relations website, with an archive accessible for one year.
Summary not available.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in Oppenheimer’s 32nd Annual Healthcare Conference on March 15-16, 2022. The management team is scheduled to present on March 15 at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days afterwards. Organogenesis focuses on regenerative medicine, offering advanced wound care and surgical products designed to meet various patient needs.
Organogenesis Holdings reported robust financial results for Q4 2021 and the fiscal year ending December 31, 2021. Q4 net revenue reached $128.6 million, a 20% increase from Q4 2020, mainly driven by a 30% growth in Advanced Wound Care products. Total net revenue for 2021 was $468.1 million, a 38% rise year-over-year. Net income soared to $51.7 million in Q4, compared to $18.3 million a year earlier. The company forecasted revenue for 2022 between $485 million and $515 million, indicating a expected growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has appointed Michael J. Driscoll, Ed.D. to its Board of Directors, effective February 15, 2022. Dr. Driscoll, an independent director, will contribute to the Audit and Nominating Committees. He brings extensive experience with 28 years in the financial services sector and 10 years in academia. His previous roles include dean of Mount St. Mary’s University and a senior executive at Adelphi University. The company's management expressed confidence in his strategic insights to bolster its operations in regenerative medicine.